Literature DB >> 7500011

Inactivated influenza virus, when presented on dendritic cells, elicits human CD8+ cytolytic T cell responses.

A Bender1, L K Bui, M A Feldman, M Larsson, N Bhardwaj.   

Abstract

Inactivated or subunit virus preparations have been excellent vaccines for inducing antibody responses. Generation of cytolytic T cell responses, however, is thought to require replicating virus, primarily to provide sufficiently large amounts of cytoplasmic proteins for processing and presentation on major histocompatibility complex class I molecules by antigen-presenting cells. Potent human CD8+ cytolytic T cell responses to live replicating influenza A virus are generated when dendritic cells are used as the antigen-presenting cells. Here, we demonstrate that dendritic cells pulsed with poorly replicating, heat- or ultraviolet-inactivated influenza virus, induce equally strong CD8+ cytolytic T lymphocyte responses. The cytotoxic T lymphocytes are generated in the apparent absence of CD4+ helper cells or exogenous cytokines. Active viral protein synthesis is not required to charge class I molecules on dendritic cells. When pulsed with inactivated virus, < 1% of dendritic cells express nonstructural protein 1, which is only synthesized in the infectious cycle. To be optimally effective, however, the inactivated virus must retain its fusogenic activity, and presumably access the cytoplasm of dendritic cells. The data indicate, therefore, that dendritic cells require only small amounts of viral protein to charge class I molecules, most likely via traditional class I processing pathways. These results reopen the potential use of inactivated virus preparations as immunogens for cytotoxic T lymphocyte responses.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7500011      PMCID: PMC2192248          DOI: 10.1084/jem.182.6.1663

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  48 in total

1.  Induction of programmed cell death (apoptosis) by influenza virus infection in tissue culture cells.

Authors:  T Takizawa; S Matsukawa; Y Higuchi; S Nakamura; Y Nakanishi; R Fukuda
Journal:  J Gen Virol       Date:  1993-11       Impact factor: 3.891

2.  HLA-B37 and HLA-A2.1 molecules bind largely nonoverlapping sets of peptides.

Authors:  B M Carreno; R W Anderson; J E Coligan; W E Biddison
Journal:  Proc Natl Acad Sci U S A       Date:  1990-05       Impact factor: 11.205

3.  Characterization of temperature sensitive influenza virus mutants defective in neuraminidase.

Authors:  P Palese; K Tobita; M Ueda; R W Compans
Journal:  Virology       Date:  1974-10       Impact factor: 3.616

4.  Influenza virus-infected dendritic cells stimulate strong proliferative and cytolytic responses from human CD8+ T cells.

Authors:  N Bhardwaj; A Bender; N Gonzalez; L K Bui; M C Garrett; R M Steinman
Journal:  J Clin Invest       Date:  1994-08       Impact factor: 14.808

Review 5.  Vaccinia virus: a tool for research and vaccine development.

Authors:  B Moss
Journal:  Science       Date:  1991-06-21       Impact factor: 47.728

6.  Priming with recombinant influenza virus followed by administration of recombinant vaccinia virus induces CD8+ T-cell-mediated protective immunity against malaria.

Authors:  S Li; M Rodrigues; D Rodriguez; J R Rodriguez; M Esteban; P Palese; R S Nussenzweig; F Zavala
Journal:  Proc Natl Acad Sci U S A       Date:  1993-06-01       Impact factor: 11.205

7.  Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome.

Authors:  R A Koup; J T Safrit; Y Cao; C A Andrews; G McLeod; W Borkowsky; C Farthing; D D Ho
Journal:  J Virol       Date:  1994-07       Impact factor: 5.103

Review 8.  Tumor antigens recognized by T lymphocytes.

Authors:  T Boon; J C Cerottini; B Van den Eynde; P van der Bruggen; A Van Pel
Journal:  Annu Rev Immunol       Date:  1994       Impact factor: 28.527

9.  A nonstructural viral protein expressed by a recombinant vaccinia virus protects against lethal cytomegalovirus infection.

Authors:  S Jonjić; M del Val; G M Keil; M J Reddehase; U H Koszinowski
Journal:  J Virol       Date:  1988-05       Impact factor: 5.103

10.  Small amounts of superantigen, when presented on dendritic cells, are sufficient to initiate T cell responses.

Authors:  N Bhardwaj; J W Young; A J Nisanian; J Baggers; R M Steinman
Journal:  J Exp Med       Date:  1993-08-01       Impact factor: 14.307

View more
  45 in total

1.  Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells.

Authors:  M V Dhodapkar; R M Steinman; M Sapp; H Desai; C Fossella; J Krasovsky; S M Donahoe; P R Dunbar; V Cerundolo; D F Nixon; N Bhardwaj
Journal:  J Clin Invest       Date:  1999-07       Impact factor: 14.808

Review 2.  RNA-transfected dendritic cells in cancer immunotherapy.

Authors:  D A Mitchell; S K Nair
Journal:  J Clin Invest       Date:  2000-11       Impact factor: 14.808

Review 3.  Active immunization of humans with dendritic cells.

Authors:  M V Dhodapkar; N Bhardwaj
Journal:  J Clin Immunol       Date:  2000-05       Impact factor: 8.317

4.  Vaccination with Bordetella pertussis-pulsed autologous or heterologous dendritic cells induces a mucosal antibody response in vivo and protects against infection.

Authors:  A George-Chandy; N Mielcarek; I Nordström; J Holmgren; K Eriksson
Journal:  Infect Immun       Date:  2001-06       Impact factor: 3.441

5.  Abortive replication of influenza virus in mouse dendritic cells.

Authors:  Lisa J Ioannidis; Erin E Verity; Simon Crawford; Steven P Rockman; Lorena E Brown
Journal:  J Virol       Date:  2012-03-14       Impact factor: 5.103

6.  IL-12 in conjunction with dendritic cells enhances antiviral CD8+ CTL responses in vitro.

Authors:  N Bhardwaj; R A Seder; A Reddy; M V Feldman
Journal:  J Clin Invest       Date:  1996-08-01       Impact factor: 14.808

Review 7.  HIV-1 and the hijacking of dendritic cells: a tug of war.

Authors:  Marie Larsson
Journal:  Springer Semin Immunopathol       Date:  2005-01

8.  Whole virus influenza vaccine activates dendritic cells (DC) and stimulates cytokine production by peripheral blood mononuclear cells (PBMC) while subunit vaccines support T cell proliferation.

Authors:  M Saurwein-Teissl; K Zisterer; T L Schmitt; R Glück; S Cryz; B Grubeck-Loebenstein
Journal:  Clin Exp Immunol       Date:  1998-11       Impact factor: 4.330

9.  Intranasal immunization with inactivated influenza virus enhances immune responses to coadministered simian-human immunodeficiency virus-like particle antigens.

Authors:  Sang-Moo Kang; Lizheng Guo; Qizhi Yao; Ioanna Skountzou; Richard W Compans
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

10.  A multisystem approach for development and evaluation of inactivated vaccines for Venezuelan equine encephalitis virus (VEEV).

Authors:  Donald L Fine; Erin Jenkins; Shannon S Martin; Pamela Glass; Michael D Parker; Brad Grimm
Journal:  J Virol Methods       Date:  2009-11-10       Impact factor: 2.014

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.